drugset / Trial / NCT01928420
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
Phase 2
Completed
30 enrolled
Humanetics Corporation
James J. Peters Veterans Affairs Medical Center · collabNational Center for Complementary and Integrative Health (NCCIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of NIC5-15 in the treatment of Alzheimer's Disease.
Timeline
- Start
- 2007-04
- Primary completion
- 2014-06
- Completion
- 2014-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIC5-15 | Small molecule | — | — |